Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — UBS Australasia Investor Conference 2016
16 slides from Mayne Pharma's conference presentation, Nov 7, 2016
Slide 1: Mayne Pharma Group Limited Company presentation
For personal use only Mayne Pharma Group Limited Company presentation UBS Australasia Investor Conference November 2016 1
Slide 2: Mayne Pharma is a specialty pharma business with diversified operations across the value chain
Mayne Pharma is a specialty pharma business with diversified operations across the value chain For personal use only Markets served by Mayne Pharma Generic Products Specialty Brands Contract Services Develops, manufactures and Develops, manufactures, markets and Provides contract pharmaceutical dist
Slide 3: Mayne Pharma key products and services
Mayne Pharma key products and services US Business Units Rest of world For personal use only Generic Products Specialty Brands Contract Services Mayne Pharma International Develops, manufactures, markets Develops, manufactures, markets Provides contract pharmaceutical Develops, manufactures, markets
Slide 4: Mayne Pharma continues to invest in its people, products, technologies and footprint
Mayne Pharma continues to invest in its people, products, technologies and footprint For personal use only A$130m+ two site A$80m+ invested capacity and Tripled staff in R&D in last 4 capability globally to 700 years and forecast expansion over last 4 years to spend A$40m+ underway in FY17 Today May
Slide 5: Investing for growth – Greenville, NC site expansion
Investing for growth – Greenville, NC site expansion For personal use only Construction status as at Sep 2016 ● New 125,000ft2 / 11,600m2 oral solid dose manufacturing facility construction commenced October 2015 ● Commercial production to migrate to new building ● Product launches remain on schedul
Slide 6: Investing for growth – research and development
Investing for growth – research and development For personal use only ● Diverse capabilities US Pipeline statistics – IMS market size (US$bn)1 – Oral (tablets and capsules) 8.0 – Topical (ointments, solutions and powders) – Potent compounds 5.0 6.0+ – DEA controlled substances 6.0 – Unstable compoun
Slide 7: 1H17 highlights
1H17 highlights For personal use only Timing Event Country Aug 2016 Completed acquisition of generic product portfolio from Teva and Allergan US Aug 2016 Acquired portfolio of foam dermatology products from GSK US Aug 2016 Doryx® MPC 120mg tablets launched US Aug 2016 Metrics Contract Services inves
Slide 8: Teva generic product acquisition update
Teva generic product acquisition update For personal use only ● Successful transition of the acquired portfolio -‐ No supply chain disruptions -‐ 80% of products now in Mayne Pharma labelling ● No.1 pipeline product – Budesonide extended-‐release capsules (generic Entocort® EC) -‐ launched on ti
Slide 9: GSK foam asset acquisition update
GSK foam asset acquisition update For personal use only ● On track to re-‐launch Fabior® and Sorilux® foam products in Q1 2017 ● In-‐sourcing of inVentiv contract sales organisation underway, effective 1 January 2017 ● Marketing campaign developed including promotional materials and sales aids ● I
Slide 10: Doryx franchise update
Doryx® franchise update For personal use only Doryx® franchise weekly prescriptions (TRx) Doryx® 50mg and 200mg franchise 7000 l Retained ~80% of doxycycline delayed-‐release (50mg and 200mg) market 6000 l ~75% of Mayne Pharma (50mg and 200mg) total 5000 prescriptions (TRx’s) now dispensed as gen
Slide 11: Dofetilide capsules – days market exclusivity
Dofetilide capsules – 180 days market exclusivity For personal use only l First generic approval to Pfizers’ Tikosyn® brand Dofetilide market weekly prescriptions (TRx) l Launched dofetilide capsules on 7 June 2016 10000 following FDA approval 9000 l Awarded 180-‐days of market exclusivity as th
Slide 12: Hedgepath Pharmaceuticals – repurposing itraconazole in cancer
Hedgepath Pharmaceuticals – repurposing itraconazole in cancer For personal use only ● Mayne Pharma owns 50% of Hedgepath Pharmaceuticals, a clinical stage company that is seeking to repurpose Mayne Pharma’s SUBA-‐Itraconazole as a potential treatment in certain cancers ● John Hopkins University di
Slide 13: Phase IIb Study of SUBA-Itraconazole in BCCNS
Phase IIb Study of SUBA-‐Itraconazole in BCCNS For personal use only l Data derived from a follow-‐on interim analysis of results in 18 subjects who have completed 16 or more weeks of SUBA-‐itraconazole dosing where no subject had demonstrated an increase in target tumour burden l The Objective
Slide 14: Phase IIb Study of SUBA-Itraconazole in BCCNS
Phase IIb Study of SUBA-‐Itraconazole in BCCNS For personal use only Complete Responses l Analysis performed on the ‘best response’ data for 231 target lesions across the 18 subjects l To date 141 lesions (61% of those studied) have responded to therapy with either a partial or complete response
Slide 15: Significant opportunities to drive growth
Significant opportunities to drive growth For personal use only ● Optimise market penetration of product portfolio ● Commercialise filed FDA products 1. US retail generics ● Leverage product portfolio in non-‐retail segments (eg. Government, universities) maximisation ● Extract synergies from recen
Slide 16: A specialty pharmaceutical company with an increasingly diversified portfolio
A specialty pharmaceutical company with an increasingly diversified For personal use only portfolio of products, technologies and footprint 16
Mayne Pharma Group — UBS Australasia Investor Conference 2016 on 6ix